Citadel Advisors
COAG

Citadel Advisors’s Hemab Therapeutics COAG Stock Holding History

Citadel Advisors’s Portfolio COAG Stock Details COAG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.2M Buy
+523,450
New +$14.4M ﹤0.01% 2644

Other funds holding COAG

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors's COAG Position: Q2 2026 in Review

Citadel Advisors opened a new position in Hemab Therapeutics (COAG) in Q2 2026: 523,450 shares worth $19.2M. The stake represents ﹤0.01% of the portfolio and ranks #2644 among its holdings.

55 funds tracked by Wall St. Rank hold COAG as of Q2 2026.

  • Citadel Advisors held 523,450 shares of Hemab Therapeutics worth $19.2M as of Q2 2026.
  • Hemab Therapeutics was a new Citadel Advisors position in Q2 2026.
  • Hemab Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #2644 holding.
  • 55 funds tracked by Wall St. Rank held Hemab Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.